{
    "nctId": "NCT01626144",
    "briefTitle": "Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles",
    "officialTitle": "Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 170,
    "primaryOutcomeMeasure": "Metabolizing enzyme genotype vs EXE metabolism profiles",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer patients who have ER+ tumors and are taking 25 mg EXE daily (orally)\n* Post-menopausal women or chemically post-menopausal women (who won't become pregnant since they are taking zoladex), or women who are post-menopausal as a result of ovary removal\n* Patients may be at any point in their hormonal treatment, but must have completed any planned surgery, radiation and chemotherapy.\n\nExclusion Criteria:\n\n* Concurrent use of corticosteroids, megestrol, or phenobarbitol (inhaled and internasal steroids are permitted)\n* History of allergy to exemestane",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}